JP2006508079A5

JP2006508079A5 -

Download PDF

Info

Publication number: JP2006508079A5
Authority: JP; Japan
Prior art keywords: group; compound; formula; product; alkyl
Prior art date: 2003-10-07
Legal status : Granted

Application number

JP2004543449A

Other languages

English (en)

Japanese (ja)

Other versions

JP2006508079A (ja

JP4664074B2 (ja

Filing date

2003-10-07

Publication date

2010-10-21

2003-10-07 Application filed filed Critical

2003-10-07 Priority claimed from PCT/US2003/031707 external-priority patent/WO2004033440A1/en

2006-03-09 Publication of JP2006508079A publication Critical patent/JP2006508079A/ja

2010-10-21 Publication of JP2006508079A5 publication Critical patent/JP2006508079A5/ja

2011-04-06 Application granted granted Critical

2011-04-06 Publication of JP4664074B2 publication Critical patent/JP4664074B2/ja

2023-10-07 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

150000001875 compounds Chemical class 0.000 claims description 413
125000001424 substituent group Chemical group 0.000 claims description 197
239000000203 mixture Substances 0.000 claims description 150
229910052739 hydrogen Inorganic materials 0.000 claims description 95
150000003839 salts Chemical class 0.000 claims description 76
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 58
239000012453 solvate Substances 0.000 claims description 55
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 48
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 45
201000010099 disease Diseases 0.000 claims description 44
125000004093 cyano group Chemical group *C#N 0.000 claims description 37
102000019034 Chemokines Human genes 0.000 claims description 30
108010012236 Chemokines Proteins 0.000 claims description 30
230000001404 mediated effect Effects 0.000 claims description 25
206010028980 Neoplasm Diseases 0.000 claims description 24
239000003814 drug Substances 0.000 claims description 21
239000008194 pharmaceutical composition Substances 0.000 claims description 20
229910052794 bromium Inorganic materials 0.000 claims description 15
239000003795 chemical substances by application Substances 0.000 claims description 14
239000003112 inhibitor Substances 0.000 claims description 13
206010061218 Inflammation Diseases 0.000 claims description 12
230000004054 inflammatory process Effects 0.000 claims description 12
150000003431 steroids Chemical class 0.000 claims description 8
239000003937 drug carrier Substances 0.000 claims description 7
239000003018 immunosuppressive agent Substances 0.000 claims description 6
229940111134 coxibs Drugs 0.000 claims description 5
229960003444 immunosuppressant agent Drugs 0.000 claims description 5
230000001861 immunosuppressant effect Effects 0.000 claims description 5
159000000007 calcium salts Chemical class 0.000 claims description 4
159000000000 sodium salts Chemical class 0.000 claims description 3
239000003260 cyclooxygenase 1 inhibitor Substances 0.000 claims description 2
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 2
238000000034 method Methods 0.000 description 363
239000000047 product Substances 0.000 description 199
230000008569 process Effects 0.000 description 190
125000000217 alkyl group Chemical group 0.000 description 136
239000000460 chlorine Substances 0.000 description 130
238000002360 preparation method Methods 0.000 description 122
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 111
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 108
239000000243 solution Substances 0.000 description 99
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 84
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 80
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 66
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 63
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 61
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 58
239000012267 brine Substances 0.000 description 57
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 57
125000001072 heteroaryl group Chemical group 0.000 description 54
239000011734 sodium Substances 0.000 description 54
238000006243 chemical reaction Methods 0.000 description 53
125000000753 cycloalkyl group Chemical group 0.000 description 53
-1 GROγ Proteins 0.000 description 51
150000001412 amines Chemical class 0.000 description 47
239000010410 layer Substances 0.000 description 47
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 44
239000007787 solid Substances 0.000 description 43
239000012044 organic layer Substances 0.000 description 42
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 42
229910052736 halogen Inorganic materials 0.000 description 38
150000002367 halogens Chemical class 0.000 description 38
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 37
125000003118 aryl group Chemical group 0.000 description 37
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 37
238000003756 stirring Methods 0.000 description 34
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 33
108010018951 Interleukin-8B Receptors Proteins 0.000 description 32
102000002791 Interleukin-8B Receptors Human genes 0.000 description 32
239000002246 antineoplastic agent Substances 0.000 description 32
238000003556 assay Methods 0.000 description 31
239000000706 filtrate Substances 0.000 description 31
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 30
239000003921 oil Substances 0.000 description 30
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 29
229910000041 hydrogen chloride Inorganic materials 0.000 description 29
229910052757 nitrogen Inorganic materials 0.000 description 29
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 28
210000004027 cell Anatomy 0.000 description 26
235000019439 ethyl acetate Nutrition 0.000 description 26
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 26
102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 description 25
101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 description 25
125000003710 aryl alkyl group Chemical group 0.000 description 25
125000001316 cycloalkyl alkyl group Chemical group 0.000 description 25
238000002821 scintillation proximity assay Methods 0.000 description 25
239000012528 membrane Substances 0.000 description 23
239000012131 assay buffer Substances 0.000 description 22
239000012043 crude product Substances 0.000 description 22
125000003709 fluoroalkyl group Chemical group 0.000 description 22
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
125000000623 heterocyclic group Chemical group 0.000 description 21
229940127089 cytotoxic agent Drugs 0.000 description 20
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 20
206010052779 Transplant rejections Diseases 0.000 description 19
230000001363 autoimmune Effects 0.000 description 19
230000001684 chronic effect Effects 0.000 description 19
239000000284 extract Substances 0.000 description 19
238000003818 flash chromatography Methods 0.000 description 19
239000011541 reaction mixture Substances 0.000 description 19
206010065390 Inflammatory pain Diseases 0.000 description 18
102100026236 Interleukin-8 Human genes 0.000 description 18
206010063837 Reperfusion injury Diseases 0.000 description 18
230000005784 autoimmunity Effects 0.000 description 18
201000011510 cancer Diseases 0.000 description 18
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 18
208000011580 syndromic disease Diseases 0.000 description 18
238000012360 testing method Methods 0.000 description 18
239000011324 bead Substances 0.000 description 17
125000004432 carbon atom Chemical group C* 0.000 description 17
125000004446 heteroarylalkyl group Chemical group 0.000 description 17
239000003446 ligand Substances 0.000 description 17
238000000746 purification Methods 0.000 description 17
206010039073 rheumatoid arthritis Diseases 0.000 description 17
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 16
108090001007 Interleukin-8 Proteins 0.000 description 16
XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 16
229940096397 interleukin-8 Drugs 0.000 description 16
201000001119 neuropathy Diseases 0.000 description 16
230000007823 neuropathy Effects 0.000 description 16
208000033808 peripheral neuropathy Diseases 0.000 description 16
238000010992 reflux Methods 0.000 description 16
108091022875 Microtubule Proteins 0.000 description 15
102000029749 Microtubule Human genes 0.000 description 15
230000000694 effects Effects 0.000 description 15
210000004688 microtubule Anatomy 0.000 description 15
230000005855 radiation Effects 0.000 description 15
239000002904 solvent Substances 0.000 description 15
239000001257 hydrogen Substances 0.000 description 14
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 14
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 13
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 13
206010003246 arthritis Diseases 0.000 description 13
229910052801 chlorine Inorganic materials 0.000 description 13
238000001816 cooling Methods 0.000 description 13
KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 13
229920006395 saturated elastomer Polymers 0.000 description 13
239000000725 suspension Substances 0.000 description 13
206010006448 Bronchiolitis Diseases 0.000 description 12
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
229930012538 Paclitaxel Natural products 0.000 description 12
206010040070 Septic Shock Diseases 0.000 description 12
241000700605 Viruses Species 0.000 description 12
125000003545 alkoxy group Chemical group 0.000 description 12
229940079593 drug Drugs 0.000 description 12
229960001592 paclitaxel Drugs 0.000 description 12
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 11
239000002253 acid Substances 0.000 description 11
230000001154 acute effect Effects 0.000 description 11
150000001299 aldehydes Chemical class 0.000 description 11
208000006673 asthma Diseases 0.000 description 11
238000001914 filtration Methods 0.000 description 11
229910052731 fluorine Inorganic materials 0.000 description 11
150000002576 ketones Chemical class 0.000 description 11
229910052717 sulfur Inorganic materials 0.000 description 11
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 10
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
206010021143 Hypoxia Diseases 0.000 description 10
208000007766 Kaposi sarcoma Diseases 0.000 description 10
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
206010047115 Vasculitis Diseases 0.000 description 10
238000004587 chromatography analysis Methods 0.000 description 10
201000008482 osteoarthritis Diseases 0.000 description 10
229910052760 oxygen Inorganic materials 0.000 description 10
229910052763 palladium Inorganic materials 0.000 description 10
229910000027 potassium carbonate Inorganic materials 0.000 description 10
125000006413 ring segment Chemical group 0.000 description 10
239000000741 silica gel Substances 0.000 description 10
229910002027 silica gel Inorganic materials 0.000 description 10
125000003107 substituted aryl group Chemical group 0.000 description 10
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 9
102000016950 Chemokine CXCL1 Human genes 0.000 description 9
239000007995 HEPES buffer Substances 0.000 description 9
208000002193 Pain Diseases 0.000 description 9
230000002378 acidificating effect Effects 0.000 description 9
208000005298 acute pain Diseases 0.000 description 9
230000002491 angiogenic effect Effects 0.000 description 9
239000012298 atmosphere Substances 0.000 description 9
230000027455 binding Effects 0.000 description 9
239000011575 calcium Substances 0.000 description 9
208000024908 graft versus host disease Diseases 0.000 description 9
208000014674 injury Diseases 0.000 description 9
208000004296 neuralgia Diseases 0.000 description 9
208000021722 neuropathic pain Diseases 0.000 description 9
208000023504 respiratory system disease Diseases 0.000 description 9
230000004043 responsiveness Effects 0.000 description 9
239000000377 silicon dioxide Substances 0.000 description 9
230000008733 trauma Effects 0.000 description 9
102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 8
101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 8
206010033645 Pancreatitis Diseases 0.000 description 8
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 8
201000004681 Psoriasis Diseases 0.000 description 8
208000007502 anemia Diseases 0.000 description 8
239000013058 crude material Substances 0.000 description 8
210000002889 endothelial cell Anatomy 0.000 description 8
208000006454 hepatitis Diseases 0.000 description 8
231100000283 hepatitis Toxicity 0.000 description 8
150000002466 imines Chemical class 0.000 description 8
201000006417 multiple sclerosis Diseases 0.000 description 8
MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 8
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 8
125000005346 substituted cycloalkyl group Chemical group 0.000 description 8
208000023275 Autoimmune disease Diseases 0.000 description 7
108050006947 CXC Chemokine Proteins 0.000 description 7
102000019388 CXC chemokine Human genes 0.000 description 7
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 7
206010016654 Fibrosis Diseases 0.000 description 7
208000006011 Stroke Diseases 0.000 description 7
150000001408 amides Chemical class 0.000 description 7
206010006451 bronchitis Diseases 0.000 description 7
229910052791 calcium Inorganic materials 0.000 description 7
208000037976 chronic inflammation Diseases 0.000 description 7
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 7
125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 7
208000030533 eye disease Diseases 0.000 description 7
125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
230000007954 hypoxia Effects 0.000 description 7
239000000543 intermediate Substances 0.000 description 7
239000002609 medium Substances 0.000 description 7
208000002574 reactive arthritis Diseases 0.000 description 7
RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 7
VQKFNUFAXTZWDK-UHFFFAOYSA-N 2-Methylfuran Chemical compound CC1=CC=CO1 VQKFNUFAXTZWDK-UHFFFAOYSA-N 0.000 description 6
WWWFHFGUOIQNJC-UHFFFAOYSA-N 2-hydroxy-3-nitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1O WWWFHFGUOIQNJC-UHFFFAOYSA-N 0.000 description 6
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 6
208000024827 Alzheimer disease Diseases 0.000 description 6
206010006458 Bronchitis chronic Diseases 0.000 description 6
206010009137 Chronic sinusitis Diseases 0.000 description 6
206010009900 Colitis ulcerative Diseases 0.000 description 6
208000011231 Crohn disease Diseases 0.000 description 6
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 6
201000003883 Cystic fibrosis Diseases 0.000 description 6
QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 6
208000000059 Dyspnea Diseases 0.000 description 6
206010013975 Dyspnoeas Diseases 0.000 description 6
206010014561 Emphysema Diseases 0.000 description 6
206010018364 Glomerulonephritis Diseases 0.000 description 6
208000009329 Graft vs Host Disease Diseases 0.000 description 6
206010020591 Hypercapnia Diseases 0.000 description 6
206010058490 Hyperoxia Diseases 0.000 description 6
208000022559 Inflammatory bowel disease Diseases 0.000 description 6
208000029523 Interstitial Lung disease Diseases 0.000 description 6
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 6
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 6
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
208000003251 Pruritus Diseases 0.000 description 6
201000001263 Psoriatic Arthritis Diseases 0.000 description 6
208000036824 Psoriatic arthropathy Diseases 0.000 description 6
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 6
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
208000007536 Thrombosis Diseases 0.000 description 6
OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 6
201000006704 Ulcerative Colitis Diseases 0.000 description 6
208000038016 acute inflammation Diseases 0.000 description 6
230000006022 acute inflammation Effects 0.000 description 6
201000000028 adult respiratory distress syndrome Diseases 0.000 description 6
125000003342 alkenyl group Chemical group 0.000 description 6
125000004183 alkoxy alkyl group Chemical group 0.000 description 6
230000033115 angiogenesis Effects 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 6
ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 6
230000000747 cardiac effect Effects 0.000 description 6
230000003197 catalytic effect Effects 0.000 description 6
208000010353 central nervous system vasculitis Diseases 0.000 description 6
208000007451 chronic bronchitis Diseases 0.000 description 6
230000006020 chronic inflammation Effects 0.000 description 6
208000027157 chronic rhinosinusitis Diseases 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
238000004440 column chromatography Methods 0.000 description 6
239000013078 crystal Substances 0.000 description 6
125000000392 cycloalkenyl group Chemical group 0.000 description 6
SPWVRYZQLGQKGK-UHFFFAOYSA-N dichloromethane;hexane Chemical compound ClCCl.CCCCCC SPWVRYZQLGQKGK-UHFFFAOYSA-N 0.000 description 6
239000003862 glucocorticoid Substances 0.000 description 6
125000005842 heteroatom Chemical group 0.000 description 6
150000002431 hydrogen Chemical class 0.000 description 6
230000000222 hyperoxic effect Effects 0.000 description 6
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Chemical group C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
230000005764 inhibitory process Effects 0.000 description 6
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 6
229960000485 methotrexate Drugs 0.000 description 6
208000031225 myocardial ischemia Diseases 0.000 description 6
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 6
239000001301 oxygen Substances 0.000 description 6
230000010412 perfusion Effects 0.000 description 6
208000005987 polymyositis Diseases 0.000 description 6
208000005069 pulmonary fibrosis Diseases 0.000 description 6
201000000306 sarcoidosis Diseases 0.000 description 6
125000000547 substituted alkyl group Chemical group 0.000 description 6
230000004614 tumor growth Effects 0.000 description 6
208000027930 type IV hypersensitivity disease Diseases 0.000 description 6
238000005406 washing Methods 0.000 description 6
IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 5
201000001320 Atherosclerosis Diseases 0.000 description 5
101001027327 Bos taurus Growth-regulated protein homolog alpha Proteins 0.000 description 5
201000006474 Brain Ischemia Diseases 0.000 description 5
108010040471 CC Chemokines Proteins 0.000 description 5
102000001902 CC Chemokines Human genes 0.000 description 5
206010008120 Cerebral ischaemia Diseases 0.000 description 5
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 5
206010012438 Dermatitis atopic Diseases 0.000 description 5
206010012689 Diabetic retinopathy Diseases 0.000 description 5
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 5
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 5
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
229940124761 MMP inhibitor Drugs 0.000 description 5
235000001014 amino acid Nutrition 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
239000004037 angiogenesis inhibitor Substances 0.000 description 5
239000005557 antagonist Substances 0.000 description 5
239000007864 aqueous solution Substances 0.000 description 5
201000008937 atopic dermatitis Diseases 0.000 description 5
150000001540 azides Chemical class 0.000 description 5
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 5
206010008118 cerebral infarction Diseases 0.000 description 5
206010012601 diabetes mellitus Diseases 0.000 description 5
239000000839 emulsion Substances 0.000 description 5
229960002949 fluorouracil Drugs 0.000 description 5
239000007788 liquid Substances 0.000 description 5
UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 5
239000000463 material Substances 0.000 description 5
229910017604 nitric acid Inorganic materials 0.000 description 5
230000000414 obstructive effect Effects 0.000 description 5
239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 5
239000000843 powder Substances 0.000 description 5
238000012746 preparative thin layer chromatography Methods 0.000 description 5
229940002612 prodrug Drugs 0.000 description 5
239000000651 prodrug Substances 0.000 description 5
208000037803 restenosis Diseases 0.000 description 5
229910052708 sodium Inorganic materials 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
239000011550 stock solution Substances 0.000 description 5
229940124597 therapeutic agent Drugs 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
OQANPHBRHBJGNZ-FYJGNVAPSA-N (3e)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 description 4
RPCHNECSJGMRGP-UHFFFAOYSA-N 3-Ethylfuran Chemical compound CCC=1C=COC=1 RPCHNECSJGMRGP-UHFFFAOYSA-N 0.000 description 4
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
208000002874 Acne Vulgaris Diseases 0.000 description 4
206010056508 Acquired epidermolysis bullosa Diseases 0.000 description 4
208000022309 Alcoholic Liver disease Diseases 0.000 description 4
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
206010059245 Angiopathy Diseases 0.000 description 4
206010002556 Ankylosing Spondylitis Diseases 0.000 description 4
208000003343 Antiphospholipid Syndrome Diseases 0.000 description 4
206010003827 Autoimmune hepatitis Diseases 0.000 description 4
206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 4
208000009137 Behcet syndrome Diseases 0.000 description 4
208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 4
208000033222 Biliary cirrhosis primary Diseases 0.000 description 4
208000019838 Blood disease Diseases 0.000 description 4
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
108010014419 Chemokine CXCL1 Proteins 0.000 description 4
208000000668 Chronic Pancreatitis Diseases 0.000 description 4
208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 4
208000015943 Coeliac disease Diseases 0.000 description 4
208000034656 Contusions Diseases 0.000 description 4
206010055665 Corneal neovascularisation Diseases 0.000 description 4
206010011224 Cough Diseases 0.000 description 4
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 4
108010036949 Cyclosporine Proteins 0.000 description 4
206010011878 Deafness Diseases 0.000 description 4
206010012442 Dermatitis contact Diseases 0.000 description 4
208000007882 Gastritis Diseases 0.000 description 4
208000007465 Giant cell arteritis Diseases 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
208000024869 Goodpasture syndrome Diseases 0.000 description 4
201000005569 Gout Diseases 0.000 description 4
206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 4
208000015023 Graves' disease Diseases 0.000 description 4
208000030836 Hashimoto thyroiditis Diseases 0.000 description 4
206010019728 Hepatitis alcoholic Diseases 0.000 description 4
241000282412 Homo Species 0.000 description 4
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
206010020751 Hypersensitivity Diseases 0.000 description 4
206010062767 Hypophysitis Diseases 0.000 description 4
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 4
208000005615 Interstitial Cystitis Diseases 0.000 description 4
UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 4
208000003456 Juvenile Arthritis Diseases 0.000 description 4
206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 4
206010024453 Ligament sprain Diseases 0.000 description 4
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
208000027530 Meniere disease Diseases 0.000 description 4
201000009906 Meningitis Diseases 0.000 description 4
208000000112 Myalgia Diseases 0.000 description 4
208000009525 Myocarditis Diseases 0.000 description 4
201000002481 Myositis Diseases 0.000 description 4
206010051606 Necrotising colitis Diseases 0.000 description 4
206010030216 Oesophagitis Diseases 0.000 description 4
208000003435 Optic Neuritis Diseases 0.000 description 4
208000001132 Osteoporosis Diseases 0.000 description 4
206010033165 Ovarian failure Diseases 0.000 description 4
206010033647 Pancreatitis acute Diseases 0.000 description 4
206010033649 Pancreatitis chronic Diseases 0.000 description 4
208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 4
206010034277 Pemphigoid Diseases 0.000 description 4
241000721454 Pemphigus Species 0.000 description 4
102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 4
206010035664 Pneumonia Diseases 0.000 description 4
208000012654 Primary biliary cholangitis Diseases 0.000 description 4
206010037549 Purpura Diseases 0.000 description 4
241001672981 Purpura Species 0.000 description 4
208000012322 Raynaud phenomenon Diseases 0.000 description 4
208000033464 Reiter syndrome Diseases 0.000 description 4
206010038933 Retinopathy of prematurity Diseases 0.000 description 4
206010039085 Rhinitis allergic Diseases 0.000 description 4
208000000924 Right ventricular hypertrophy Diseases 0.000 description 4
206010039705 Scleritis Diseases 0.000 description 4
206010039710 Scleroderma Diseases 0.000 description 4
208000021386 Sjogren Syndrome Diseases 0.000 description 4
208000010040 Sprains and Strains Diseases 0.000 description 4
208000005718 Stomach Neoplasms Diseases 0.000 description 4
208000007107 Stomach Ulcer Diseases 0.000 description 4
208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 4
206010044248 Toxic shock syndrome Diseases 0.000 description 4
231100000650 Toxic shock syndrome Toxicity 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
206010046851 Uveitis Diseases 0.000 description 4
108091008605 VEGF receptors Proteins 0.000 description 4
102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 4
206010047642 Vitiligo Diseases 0.000 description 4
150000007513 acids Chemical class 0.000 description 4
206010000496 acne Diseases 0.000 description 4
201000003229 acute pancreatitis Diseases 0.000 description 4
208000002353 alcoholic hepatitis Diseases 0.000 description 4
125000000304 alkynyl group Chemical group 0.000 description 4
208000002029 allergic contact dermatitis Diseases 0.000 description 4
208000026935 allergic disease Diseases 0.000 description 4
201000010105 allergic rhinitis Diseases 0.000 description 4
208000004631 alopecia areata Diseases 0.000 description 4
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
201000004339 autoimmune neuropathy Diseases 0.000 description 4
208000000594 bullous pemphigoid Diseases 0.000 description 4
208000025997 central nervous system neoplasm Diseases 0.000 description 4
230000035605 chemotaxis Effects 0.000 description 4
229940044683 chemotherapy drug Drugs 0.000 description 4
201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 4
229960001265 ciclosporin Drugs 0.000 description 4
230000007882 cirrhosis Effects 0.000 description 4
208000019425 cirrhosis of liver Diseases 0.000 description 4
230000009519 contusion Effects 0.000 description 4
201000000159 corneal neovascularization Diseases 0.000 description 4
201000003278 cryoglobulinemia Diseases 0.000 description 4
125000004122 cyclic group Chemical group 0.000 description 4
229930182912 cyclosporin Natural products 0.000 description 4
201000001981 dermatomyositis Diseases 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 4
208000000718 duodenal ulcer Diseases 0.000 description 4
208000000292 ehrlichiosis Diseases 0.000 description 4
206010014599 encephalitis Diseases 0.000 description 4
201000011114 epidermolysis bullosa acquisita Diseases 0.000 description 4
208000006881 esophagitis Diseases 0.000 description 4
150000002148 esters Chemical class 0.000 description 4
239000003172 expectorant agent Substances 0.000 description 4
238000009472 formulation Methods 0.000 description 4
239000012458 free base Substances 0.000 description 4
125000000524 functional group Chemical group 0.000 description 4
206010017758 gastric cancer Diseases 0.000 description 4
201000005917 gastric ulcer Diseases 0.000 description 4
208000007565 gingivitis Diseases 0.000 description 4
210000003714 granulocyte Anatomy 0.000 description 4
230000036541 health Effects 0.000 description 4
230000010370 hearing loss Effects 0.000 description 4
231100000888 hearing loss Toxicity 0.000 description 4
208000016354 hearing loss disease Diseases 0.000 description 4
208000014951 hematologic disease Diseases 0.000 description 4
208000018706 hematopoietic system disease Diseases 0.000 description 4
230000002949 hemolytic effect Effects 0.000 description 4
230000009610 hypersensitivity Effects 0.000 description 4
239000005457 ice water Substances 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
229910052740 iodine Inorganic materials 0.000 description 4
239000011630 iodine Substances 0.000 description 4
238000012417 linear regression Methods 0.000 description 4
210000004072 lung Anatomy 0.000 description 4
206010025135 lupus erythematosus Diseases 0.000 description 4
208000002780 macular degeneration Diseases 0.000 description 4
201000004792 malaria Diseases 0.000 description 4
201000001441 melanoma Diseases 0.000 description 4
229910052751 metal Inorganic materials 0.000 description 4
239000002184 metal Substances 0.000 description 4
230000011278 mitosis Effects 0.000 description 4
230000008383 multiple organ dysfunction Effects 0.000 description 4
206010028417 myasthenia gravis Diseases 0.000 description 4
208000004995 necrotizing enterocolitis Diseases 0.000 description 4
210000000440 neutrophil Anatomy 0.000 description 4
201000004535 ovarian dysfunction Diseases 0.000 description 4
231100000539 ovarian failure Toxicity 0.000 description 4
201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 4
201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 4
206010034674 peritonitis Diseases 0.000 description 4
239000002244 precipitate Substances 0.000 description 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
230000002685 pulmonary effect Effects 0.000 description 4
208000002815 pulmonary hypertension Diseases 0.000 description 4
238000001959 radiotherapy Methods 0.000 description 4
230000000241 respiratory effect Effects 0.000 description 4
230000036303 septic shock Effects 0.000 description 4
208000000649 small cell carcinoma Diseases 0.000 description 4
241000894007 species Species 0.000 description 4
201000011549 stomach cancer Diseases 0.000 description 4
NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 4
229960001940 sulfasalazine Drugs 0.000 description 4
201000000596 systemic lupus erythematosus Diseases 0.000 description 4
206010043207 temporal arteritis Diseases 0.000 description 4
XWMXMWHHTIEXRE-UHFFFAOYSA-N thiadiazole 1-oxide Chemical class O=S1C=CN=N1 XWMXMWHHTIEXRE-UHFFFAOYSA-N 0.000 description 4
206010043554 thrombocytopenia Diseases 0.000 description 4
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
241001529453 unidentified herpesvirus Species 0.000 description 4
238000009423 ventilation Methods 0.000 description 4
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 4
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 4
229960004528 vincristine Drugs 0.000 description 4
206010047470 viral myocarditis Diseases 0.000 description 4
239000011534 wash buffer Substances 0.000 description 4
XOFLBQFBSOEHOG-UUOKFMHZSA-N γS-GTP Chemical group C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=S)[C@@H](O)[C@H]1O XOFLBQFBSOEHOG-UUOKFMHZSA-N 0.000 description 4
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
229920001817 Agar Polymers 0.000 description 3
206010003267 Arthritis reactive Diseases 0.000 description 3
208000023328 Basedow disease Diseases 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
102100036150 C-X-C motif chemokine 5 Human genes 0.000 description 3
229940124638 COX inhibitor Drugs 0.000 description 3
108091008928 CXC chemokine receptors Proteins 0.000 description 3
102000054900 CXCR Receptors Human genes 0.000 description 3
201000009273 Endometriosis Diseases 0.000 description 3
206010015943 Eye inflammation Diseases 0.000 description 3
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
208000005232 Glossitis Diseases 0.000 description 3
101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
102000014150 Interferons Human genes 0.000 description 3
108010050904 Interferons Proteins 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
201000005099 Langerhans cell histiocytosis Diseases 0.000 description 3
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
201000003793 Myelodysplastic syndrome Diseases 0.000 description 3
150000001204 N-oxides Chemical class 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
208000006399 Premature Obstetric Labor Diseases 0.000 description 3
206010036600 Premature labour Diseases 0.000 description 3
208000002200 Respiratory Hypersensitivity Diseases 0.000 description 3
229940124639 Selective inhibitor Drugs 0.000 description 3
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 3
208000030886 Traumatic Brain injury Diseases 0.000 description 3
206010048302 Tubulointerstitial nephritis Diseases 0.000 description 3
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 3
150000008043 acidic salts Chemical class 0.000 description 3
239000008272 agar Substances 0.000 description 3
230000010085 airway hyperresponsiveness Effects 0.000 description 3
150000001447 alkali salts Chemical class 0.000 description 3
125000003277 amino group Chemical group 0.000 description 3
239000003963 antioxidant agent Substances 0.000 description 3
230000003078 antioxidant effect Effects 0.000 description 3
235000006708 antioxidants Nutrition 0.000 description 3
125000004429 atom Chemical group 0.000 description 3
201000005008 bacterial sepsis Diseases 0.000 description 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
229960002537 betamethasone Drugs 0.000 description 3
UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
229910000085 borane Inorganic materials 0.000 description 3
230000007883 bronchodilation Effects 0.000 description 3
229910052799 carbon Inorganic materials 0.000 description 3
239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
239000000969 carrier Substances 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
125000001309 chloro group Chemical group Cl* 0.000 description 3
239000012141 concentrate Substances 0.000 description 3
238000009833 condensation Methods 0.000 description 3
230000005494 condensation Effects 0.000 description 3
230000008878 coupling Effects 0.000 description 3
238000010168 coupling process Methods 0.000 description 3
238000005859 coupling reaction Methods 0.000 description 3
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 3
229960004397 cyclophosphamide Drugs 0.000 description 3
NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 3
UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
230000004761 fibrosis Effects 0.000 description 3
239000011737 fluorine Substances 0.000 description 3
125000001153 fluoro group Chemical group F* 0.000 description 3
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 3
229960005277 gemcitabine Drugs 0.000 description 3
125000002768 hydroxyalkyl group Chemical group 0.000 description 3
208000018875 hypoxemia Diseases 0.000 description 3
238000011534 incubation Methods 0.000 description 3
229940079322 interferon Drugs 0.000 description 3
201000006334 interstitial nephritis Diseases 0.000 description 3
201000011486 lichen planus Diseases 0.000 description 3
DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 3
UFTXASQYKJFRKI-UHFFFAOYSA-N methyl 4-bromo-3-hydroxythiophene-2-carboxylate Chemical compound COC(=O)C=1SC=C(Br)C=1O UFTXASQYKJFRKI-UHFFFAOYSA-N 0.000 description 3
201000008383 nephritis Diseases 0.000 description 3
239000012074 organic phase Substances 0.000 description 3
YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 3
229960002340 pentostatin Drugs 0.000 description 3
FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 3
201000001245 periodontitis Diseases 0.000 description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
208000026440 premature labor Diseases 0.000 description 3
239000000376 reactant Substances 0.000 description 3
238000010898 silica gel chromatography Methods 0.000 description 3
235000017557 sodium bicarbonate Nutrition 0.000 description 3
229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
229910000104 sodium hydride Inorganic materials 0.000 description 3
FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
229910052938 sodium sulfate Inorganic materials 0.000 description 3
235000011152 sodium sulphate Nutrition 0.000 description 3
239000011593 sulfur Substances 0.000 description 3
125000004434 sulfur atom Chemical group 0.000 description 3
229940037128 systemic glucocorticoids Drugs 0.000 description 3
229960004964 temozolomide Drugs 0.000 description 3
LKHDXIBHVSGUHN-UHFFFAOYSA-N thiadiazole 1,1-dioxide Chemical class O=S1(=O)C=CN=N1 LKHDXIBHVSGUHN-UHFFFAOYSA-N 0.000 description 3
208000009174 transverse myelitis Diseases 0.000 description 3
230000009529 traumatic brain injury Effects 0.000 description 3
210000004881 tumor cell Anatomy 0.000 description 3
DLMYFMLKORXJPO-FQEVSTJZSA-N (2R)-2-amino-3-[(triphenylmethyl)thio]propanoic acid Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(SC[C@H](N)C(O)=O)C1=CC=CC=C1 DLMYFMLKORXJPO-FQEVSTJZSA-N 0.000 description 2
FYCRNRZIEVLZDO-BYPYZUCNSA-N (2s)-morpholin-4-ium-2-carboxylate Chemical compound OC(=O)[C@@H]1CNCCO1 FYCRNRZIEVLZDO-BYPYZUCNSA-N 0.000 description 2
JHHZLHWJQPUNKB-SCSAIBSYSA-N (3r)-pyrrolidin-3-ol Chemical compound O[C@@H]1CCNC1 JHHZLHWJQPUNKB-SCSAIBSYSA-N 0.000 description 2
FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 2
125000006273 (C1-C3) alkyl group Chemical group 0.000 description 2
MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 description 2
FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 2
GWNVDXQDILPJIG-CCHJCNDSSA-N 11-trans-Leukotriene C4 Chemical compound CCCCC\C=C/C\C=C\C=C\C=C\[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-CCHJCNDSSA-N 0.000 description 2
QENGPZGAWFQWCZ-UHFFFAOYSA-N 3-Methylthiophene Chemical compound CC=1C=CSC=1 QENGPZGAWFQWCZ-UHFFFAOYSA-N 0.000 description 2
SBTKGYVVXLMMQE-UHFFFAOYSA-N 3-butylfuran Chemical compound CCCCC=1C=COC=1 SBTKGYVVXLMMQE-UHFFFAOYSA-N 0.000 description 2
HLKHDXRCRNEXSF-UHFFFAOYSA-N 3-methoxythiophene-2-sulfonyl chloride Chemical compound COC=1C=CSC=1S(Cl)(=O)=O HLKHDXRCRNEXSF-UHFFFAOYSA-N 0.000 description 2
239000003185 4 aminobutyric acid B receptor stimulating agent Substances 0.000 description 2
LEEPGDCCHVRYHK-UHFFFAOYSA-N 4-bromo-1-methylpyrazole-3-carboxylic acid Chemical compound CN1C=C(Br)C(C(O)=O)=N1 LEEPGDCCHVRYHK-UHFFFAOYSA-N 0.000 description 2
OLDGPQVUEMIBNR-UHFFFAOYSA-N 4-bromo-3-methoxythiophene-2-carboxylic acid Chemical compound COC=1C(Br)=CSC=1C(O)=O OLDGPQVUEMIBNR-UHFFFAOYSA-N 0.000 description 2
229940124125 5 Lipoxygenase inhibitor Drugs 0.000 description 2
FKPXGNGUVSHWQQ-UHFFFAOYSA-N 5-methyl-1,2-oxazol-3-amine Chemical compound CC1=CC(N)=NO1 FKPXGNGUVSHWQQ-UHFFFAOYSA-N 0.000 description 2
OUDFNZMQXZILJD-UHFFFAOYSA-N 5-methyl-2-furaldehyde Chemical compound CC1=CC=C(C=O)O1 OUDFNZMQXZILJD-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
206010003210 Arteriosclerosis Diseases 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
102100039705 Beta-2 adrenergic receptor Human genes 0.000 description 2
102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
102100039398 C-X-C motif chemokine 2 Human genes 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 2
MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 2
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
229940122858 Elastase inhibitor Drugs 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
QGWNDRXFNXRZMB-UUOKFMHZSA-K GDP(3-) Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O QGWNDRXFNXRZMB-UUOKFMHZSA-K 0.000 description 2
108010051696 Growth Hormone Proteins 0.000 description 2
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
239000012981 Hank's balanced salt solution Substances 0.000 description 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 description 2
101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 2
XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 2
XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 2
239000000867 Lipoxygenase Inhibitor Substances 0.000 description 2
208000019693 Lung disease Diseases 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
206010065673 Nephritic syndrome Diseases 0.000 description 2
108010014865 PLIalpha Proteins 0.000 description 2
229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 2
229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 2
229940123898 Phospholipase A2 inhibitor Drugs 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
102100038803 Somatotropin Human genes 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
108010039185 Tenecteplase Proteins 0.000 description 2
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
241000534944 Thia Species 0.000 description 2
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 2
229960000446 abciximab Drugs 0.000 description 2
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
230000004913 activation Effects 0.000 description 2
239000002597 adenosine A2 receptor agonist Substances 0.000 description 2
239000000048 adrenergic agonist Substances 0.000 description 2
229940126157 adrenergic receptor agonist Drugs 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
239000000556 agonist Substances 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
125000001931 aliphatic group Chemical group 0.000 description 2
229940100198 alkylating agent Drugs 0.000 description 2
239000002168 alkylating agent Substances 0.000 description 2
229960003318 alteplase Drugs 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
239000002260 anti-inflammatory agent Substances 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
230000000340 anti-metabolite Effects 0.000 description 2
230000000259 anti-tumor effect Effects 0.000 description 2
229940100197 antimetabolite Drugs 0.000 description 2
239000002256 antimetabolite Substances 0.000 description 2
229940034982 antineoplastic agent Drugs 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
125000001246 bromo group Chemical group Br* 0.000 description 2
229940124630 bronchodilator Drugs 0.000 description 2
239000000872 buffer Substances 0.000 description 2
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 2
239000002775 capsule Substances 0.000 description 2
125000002837 carbocyclic group Chemical group 0.000 description 2
229910002091 carbon monoxide Inorganic materials 0.000 description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
150000001735 carboxylic acids Chemical class 0.000 description 2
230000008859 change Effects 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
229960004544 cortisone Drugs 0.000 description 2
238000002784 cytotoxicity assay Methods 0.000 description 2
231100000263 cytotoxicity test Toxicity 0.000 description 2
239000000850 decongestant Substances 0.000 description 2
238000000280 densification Methods 0.000 description 2
229960003957 dexamethasone Drugs 0.000 description 2
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
DAKIDYQCFJQMDF-UHFFFAOYSA-N dichloromethane;pyridine Chemical compound ClCCl.C1=CC=NC=C1 DAKIDYQCFJQMDF-UHFFFAOYSA-N 0.000 description 2
OFDNQWIFNXBECV-VFSYNPLYSA-N dolastatin 10 Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-VFSYNPLYSA-N 0.000 description 2
108010045524 dolastatin 10 Proteins 0.000 description 2
239000003136 dopamine receptor stimulating agent Substances 0.000 description 2
238000009510 drug design Methods 0.000 description 2
239000003602 elastase inhibitor Substances 0.000 description 2
229960001842 estramustine Drugs 0.000 description 2
FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
230000003419 expectorant effect Effects 0.000 description 2
GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
239000007789 gas Substances 0.000 description 2
YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 2
150000004795 grignard reagents Chemical class 0.000 description 2
230000012010 growth Effects 0.000 description 2
239000000122 growth hormone Substances 0.000 description 2
QGWNDRXFNXRZMB-UHFFFAOYSA-N guanidine diphosphate Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O QGWNDRXFNXRZMB-UHFFFAOYSA-N 0.000 description 2
125000005843 halogen group Chemical group 0.000 description 2
229960002897 heparin Drugs 0.000 description 2
229920000669 heparin Polymers 0.000 description 2
125000004366 heterocycloalkenyl group Chemical group 0.000 description 2
125000000592 heterocycloalkyl group Chemical group 0.000 description 2
125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 2
GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 2
239000000938 histamine H1 antagonist Substances 0.000 description 2
239000003395 histamine H3 receptor antagonist Substances 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
150000003840 hydrochlorides Chemical class 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
229960000908 idarubicin Drugs 0.000 description 2
238000000099 in vitro assay Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
229960000598 infliximab Drugs 0.000 description 2
125000002346 iodo group Chemical group I* 0.000 description 2
229940043355 kinase inhibitor Drugs 0.000 description 2
VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 2
239000003199 leukotriene receptor blocking agent Substances 0.000 description 2
HSZCZNFXUDYRKD-UHFFFAOYSA-M lithium iodide Chemical compound [Li+].[I-] HSZCZNFXUDYRKD-UHFFFAOYSA-M 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
235000019341 magnesium sulphate Nutrition 0.000 description 2
FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 2
229960004961 mechlorethamine Drugs 0.000 description 2
HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 2
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
229960001156 mitoxantrone Drugs 0.000 description 2
239000003068 molecular probe Substances 0.000 description 2
229940066491 mucolytics Drugs 0.000 description 2
239000000234 muscarinic M1 receptor antagonist Substances 0.000 description 2
239000000536 muscarinic M2 receptor agonist Substances 0.000 description 2
229930014626 natural product Natural products 0.000 description 2
239000002742 neurokinin 1 receptor antagonist Substances 0.000 description 2
239000002746 neurokinin 2 receptor antagonist Substances 0.000 description 2
239000002740 neurokinin 3 receptor antagonist Substances 0.000 description 2
239000002762 nociceptin receptor agonist Substances 0.000 description 2
201000005737 orchitis Diseases 0.000 description 2
150000002923 oximes Chemical class 0.000 description 2
239000008188 pellet Substances 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
239000003358 phospholipase A2 inhibitor Substances 0.000 description 2
239000003757 phosphotransferase inhibitor Substances 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229910052697 platinum Inorganic materials 0.000 description 2
229920001296 polysiloxane Polymers 0.000 description 2
FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
229960004618 prednisone Drugs 0.000 description 2
230000002265 prevention Effects 0.000 description 2
DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
238000012216 screening Methods 0.000 description 2
229910052710 silicon Inorganic materials 0.000 description 2
239000010703 silicon Substances 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
239000008247 solid mixture Substances 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
229960000216 tenecteplase Drugs 0.000 description 2
AKQXKEBCONUWCL-UHFFFAOYSA-N tert-butyl 3-aminopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(N)C1 AKQXKEBCONUWCL-UHFFFAOYSA-N 0.000 description 2
FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
238000002054 transplantation Methods 0.000 description 2
WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
230000005747 tumor angiogenesis Effects 0.000 description 2
230000005951 type IV hypersensitivity Effects 0.000 description 2
208000019553 vascular disease Diseases 0.000 description 2
AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 2
AADVCYNFEREWOS-UHFFFAOYSA-N (+)-DDM Natural products C=CC=CC(C)C(OC(N)=O)C(C)C(O)C(C)CC(C)=CC(C)C(O)C(C)C=CC(O)CC1OC(=O)C(C)C(O)C1C AADVCYNFEREWOS-UHFFFAOYSA-N 0.000 description 1
FLBKPDIBGNWXMT-NIQZGXKPSA-N (2r,3r,4s,5r)-2-[6-amino-2-[[(2s)-1-hydroxy-3-phenylpropan-2-yl]amino]purin-9-yl]-5-(2-ethyltetrazol-5-yl)oxolane-3,4-diol Chemical compound CCN1N=NC([C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC(N[C@H](CO)CC=4C=CC=CC=4)=NC(N)=C3N=C2)O)=N1 FLBKPDIBGNWXMT-NIQZGXKPSA-N 0.000 description 1
HONKEGXLWUDTCF-YFKPBYRVSA-N (2s)-2-amino-2-methyl-4-phosphonobutanoic acid Chemical compound OC(=O)[C@](N)(C)CCP(O)(O)=O HONKEGXLWUDTCF-YFKPBYRVSA-N 0.000 description 1
XLMSKXASROPJNG-RXMQYKEDSA-N (2s)-2-amino-2-thiophen-2-ylacetic acid Chemical compound OC(=O)[C@H](N)C1=CC=CS1 XLMSKXASROPJNG-RXMQYKEDSA-N 0.000 description 1
SZXBQTSZISFIAO-ZETCQYMHSA-N (2s)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)OC(C)(C)C SZXBQTSZISFIAO-ZETCQYMHSA-N 0.000 description 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
BUMMZWFWCNQFPS-BTJKTKAUSA-N (z)-but-2-enedioic acid;4-[5-(4-carbamimidoylphenoxy)pentoxy]-3-methoxy-n,n-di(propan-2-yl)benzamide Chemical compound OC(=O)\C=C/C(O)=O.COC1=CC(C(=O)N(C(C)C)C(C)C)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 BUMMZWFWCNQFPS-BTJKTKAUSA-N 0.000 description 1
125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 1
KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
RHXUHAVACBNNSU-UHFFFAOYSA-N 1-[2-(dimethylamino)ethyl]-1-(3,4,5-trimethoxyphenyl)urea Chemical compound COC1=CC(N(CCN(C)C)C(N)=O)=CC(OC)=C1OC RHXUHAVACBNNSU-UHFFFAOYSA-N 0.000 description 1
102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
MLEGMEBCXGDFQT-UHFFFAOYSA-N 1-benzylpiperidin-2-one Chemical compound O=C1CCCCN1CC1=CC=CC=C1 MLEGMEBCXGDFQT-UHFFFAOYSA-N 0.000 description 1
ZNRFPPAXFPJZRQ-UHFFFAOYSA-N 1-bromo-1,1-difluoropropane Chemical compound CCC(F)(F)Br ZNRFPPAXFPJZRQ-UHFFFAOYSA-N 0.000 description 1
VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 1
DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 description 1
YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
CZYKJGCKVBXLGF-UHFFFAOYSA-N 2,2,2-trifluoro-1-thiophen-2-ylethanone Chemical compound FC(F)(F)C(=O)C1=CC=CS1 CZYKJGCKVBXLGF-UHFFFAOYSA-N 0.000 description 1
ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
KGSVNOLLROCJQM-UHFFFAOYSA-N 2-(benzylamino)acetic acid Chemical compound OC(=O)CNCC1=CC=CC=C1 KGSVNOLLROCJQM-UHFFFAOYSA-N 0.000 description 1
MFPZQZZWAMAHOY-UHFFFAOYSA-N 2-Propanoylthiophene Chemical compound CCC(=O)C1=CC=CS1 MFPZQZZWAMAHOY-UHFFFAOYSA-N 0.000 description 1
LDPCPYNFUFQWDZ-UHFFFAOYSA-N 2-[(2-ethyl-3-methoxyphenyl)methylsulfonyl]thiophene Chemical compound C1=CC=C(OC)C(CC)=C1CS(=O)(=O)C1=CC=CS1 LDPCPYNFUFQWDZ-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
VGZREXZCXACRQU-UHFFFAOYSA-N 2-aminothiophen-3-ol Chemical compound NC=1SC=CC=1O VGZREXZCXACRQU-UHFFFAOYSA-N 0.000 description 1
LILXDMFJXYAKMK-UHFFFAOYSA-N 2-bromo-1,1-diethoxyethane Chemical compound CCOC(CBr)OCC LILXDMFJXYAKMK-UHFFFAOYSA-N 0.000 description 1
125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
DLGBEGBHXSAQOC-UHFFFAOYSA-N 2-hydroxy-5-methylbenzoic acid Chemical compound CC1=CC=C(O)C(C(O)=O)=C1 DLGBEGBHXSAQOC-UHFFFAOYSA-N 0.000 description 1
CHZCERSEMVWNHL-UHFFFAOYSA-N 2-hydroxybenzonitrile Chemical compound OC1=CC=CC=C1C#N CHZCERSEMVWNHL-UHFFFAOYSA-N 0.000 description 1
GZJIQNJINXQYTG-UHFFFAOYSA-N 2-nitrooxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1O[N+]([O-])=O GZJIQNJINXQYTG-UHFFFAOYSA-N 0.000 description 1
FGLBSLMDCBOPQK-UHFFFAOYSA-N 2-nitropropane Chemical compound CC(C)[N+]([O-])=O FGLBSLMDCBOPQK-UHFFFAOYSA-N 0.000 description 1
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
FIDWUJWRKJJJLL-UHFFFAOYSA-N 3-[2-(4-hydroxy-2-oxo-3h-1,3-benzothiazol-7-yl)ethylamino]-n-[2-[2-(4-methylphenyl)ethoxy]ethyl]propane-1-sulfonamide Chemical compound C1=CC(C)=CC=C1CCOCCNS(=O)(=O)CCCNCCC1=CC=C(O)C2=C1SC(=O)N2 FIDWUJWRKJJJLL-UHFFFAOYSA-N 0.000 description 1
VLLMILLTHUWJHA-UHFFFAOYSA-N 3-amino-2-hydroxy-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(N)=C1O VLLMILLTHUWJHA-UHFFFAOYSA-N 0.000 description 1
MNOJRWOWILAHAV-UHFFFAOYSA-N 3-bromophenol Chemical compound OC1=CC=CC(Br)=C1 MNOJRWOWILAHAV-UHFFFAOYSA-N 0.000 description 1
DXAQRDRNGATBSU-UHFFFAOYSA-N 3-butylfuran-2-carbaldehyde Chemical compound CCCCC=1C=COC=1C=O DXAQRDRNGATBSU-UHFFFAOYSA-N 0.000 description 1
SRWILAKSARHZPR-UHFFFAOYSA-N 3-chlorobenzaldehyde Chemical compound ClC1=CC=CC(C=O)=C1 SRWILAKSARHZPR-UHFFFAOYSA-N 0.000 description 1
AZVSIHIBYRHSLB-UHFFFAOYSA-N 3-furaldehyde Chemical compound O=CC=1C=COC=1 AZVSIHIBYRHSLB-UHFFFAOYSA-N 0.000 description 1
BIAVGWDGIJKWRM-FQEVSTJZSA-N 3-hydroxy-2-phenyl-n-[(1s)-1-phenylpropyl]quinoline-4-carboxamide Chemical compound N([C@@H](CC)C=1C=CC=CC=1)C(=O)C(C1=CC=CC=C1N=1)=C(O)C=1C1=CC=CC=C1 BIAVGWDGIJKWRM-FQEVSTJZSA-N 0.000 description 1
RFSKGCVUDQRZSD-UHFFFAOYSA-N 3-methoxythiophene Chemical compound COC=1C=CSC=1 RFSKGCVUDQRZSD-UHFFFAOYSA-N 0.000 description 1
IOCXBXZBNOYTLQ-UHFFFAOYSA-N 3-nitrobenzene-1,2-diamine Chemical compound NC1=CC=CC([N+]([O-])=O)=C1N IOCXBXZBNOYTLQ-UHFFFAOYSA-N 0.000 description 1
AFPHTEQTJZKQAQ-UHFFFAOYSA-N 3-nitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1 AFPHTEQTJZKQAQ-UHFFFAOYSA-N 0.000 description 1
AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
SCJCDNUXDWFVFI-UHFFFAOYSA-N 4,4,4-trifluorobutanal Chemical compound FC(F)(F)CCC=O SCJCDNUXDWFVFI-UHFFFAOYSA-N 0.000 description 1
FYNWIUIVGCNYLL-UHFFFAOYSA-N 4,5-dimethoxythiadiazole 1,1-dioxide Chemical compound COC1=C(OC)S(=O)(=O)N=N1 FYNWIUIVGCNYLL-UHFFFAOYSA-N 0.000 description 1
DHTVHFHZXOMYBI-UHFFFAOYSA-N 4,5-dimethoxythiadiazole 1-oxide Chemical compound COC=1N=NS(=O)C=1OC DHTVHFHZXOMYBI-UHFFFAOYSA-N 0.000 description 1
LGWMTRPJZFEWCX-UHFFFAOYSA-N 4-[(2-methylpropan-2-yl)oxycarbonyl]morpholine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCOC(C(O)=O)C1 LGWMTRPJZFEWCX-UHFFFAOYSA-N 0.000 description 1
MRGBBKQOSUHKPF-UHFFFAOYSA-N 4-bromofuran-2-carbaldehyde Chemical compound BrC1=COC(C=O)=C1 MRGBBKQOSUHKPF-UHFFFAOYSA-N 0.000 description 1
GZFGOTFRPZRKDS-UHFFFAOYSA-N 4-bromophenol Chemical compound OC1=CC=C(Br)C=C1 GZFGOTFRPZRKDS-UHFFFAOYSA-N 0.000 description 1
KYOQLZOZPDVYCB-UHFFFAOYSA-N 4-ethylfuran-2-carbaldehyde Chemical compound CCC1=COC(C=O)=C1 KYOQLZOZPDVYCB-UHFFFAOYSA-N 0.000 description 1
CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 description 1
DITXQIKOEIMHOI-UHFFFAOYSA-N 4-methoxythiadiazole 1,1-dioxide Chemical compound COC1=CS(=O)(=O)N=N1 DITXQIKOEIMHOI-UHFFFAOYSA-N 0.000 description 1
IVNPXOUPZCTJAK-UHFFFAOYSA-N 4-methylmorpholin-4-ium;hydroxide Chemical compound O.CN1CCOCC1 IVNPXOUPZCTJAK-UHFFFAOYSA-N 0.000 description 1
WPXHBJUNZGWFJD-UHFFFAOYSA-N 4-methylpyrimidin-5-ol Chemical compound CC1=NC=NC=C1O WPXHBJUNZGWFJD-UHFFFAOYSA-N 0.000 description 1
NJESAXZANHETJV-UHFFFAOYSA-N 4-methylsalicylic acid Chemical compound CC1=CC=C(C(O)=O)C(O)=C1 NJESAXZANHETJV-UHFFFAOYSA-N 0.000 description 1
UKWUOTZGXIZAJC-UHFFFAOYSA-N 4-nitrosalicylic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C=C1O UKWUOTZGXIZAJC-UHFFFAOYSA-N 0.000 description 1
CHCUBGPSZDGABM-UHFFFAOYSA-N 4-oxo-1h-pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CNC=CC1=O CHCUBGPSZDGABM-UHFFFAOYSA-N 0.000 description 1
MQLADKMVHOOVET-HXPMCKFVSA-N 5-[4-[(2s,4r)-4-hydroxy-2-methyloxan-4-yl]thiophen-2-yl]sulfanyl-1-methyl-3h-indol-2-one Chemical compound C1CO[C@@H](C)C[C@@]1(O)C1=CSC(SC=2C=C3CC(=O)N(C)C3=CC=2)=C1 MQLADKMVHOOVET-HXPMCKFVSA-N 0.000 description 1
IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
VXPXTXPNYIZMLU-UHFFFAOYSA-N 5-bromo-4-tert-butyl-2-ethyl-3H-furan-2-carboxylic acid Chemical compound CCC1(C(O)=O)CC(C(C)(C)C)=C(Br)O1 VXPXTXPNYIZMLU-UHFFFAOYSA-N 0.000 description 1
YVTQHZDUDUCGRD-UHFFFAOYSA-N 5-bromofuran-2-carboxylic acid Chemical compound OC(=O)C1=CC=C(Br)O1 YVTQHZDUDUCGRD-UHFFFAOYSA-N 0.000 description 1
NKBASRXWGAGQDP-UHFFFAOYSA-N 5-chlorosalicylic acid Chemical compound OC(=O)C1=CC(Cl)=CC=C1O NKBASRXWGAGQDP-UHFFFAOYSA-N 0.000 description 1
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 1
206010063409 Acarodermatitis Diseases 0.000 description 1
208000030090 Acute Disease Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
108010024976 Asparaginase Proteins 0.000 description 1
208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
206010003645 Atopy Diseases 0.000 description 1
NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
108010006654 Bleomycin Proteins 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
102100036842 C-C motif chemokine 19 Human genes 0.000 description 1
102100036846 C-C motif chemokine 21 Human genes 0.000 description 1
102100036850 C-C motif chemokine 23 Human genes 0.000 description 1
102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
102100032366 C-C motif chemokine 7 Human genes 0.000 description 1
101710155834 C-C motif chemokine 7 Proteins 0.000 description 1
102100034871 C-C motif chemokine 8 Human genes 0.000 description 1
101710155833 C-C motif chemokine 8 Proteins 0.000 description 1
102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 1
102100036153 C-X-C motif chemokine 6 Human genes 0.000 description 1
101710085504 C-X-C motif chemokine 6 Proteins 0.000 description 1
102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 1
101710085500 C-X-C motif chemokine 9 Proteins 0.000 description 1
108700012434 CCL3 Proteins 0.000 description 1
LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 1
DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
208000035484 Cellulite Diseases 0.000 description 1
102000000013 Chemokine CCL3 Human genes 0.000 description 1
108010055166 Chemokine CCL5 Proteins 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
102000004266 Collagen Type IV Human genes 0.000 description 1
108010042086 Collagen Type IV Proteins 0.000 description 1
MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
HVVNJUAVDAZWCB-RXMQYKEDSA-N D-prolinol Chemical compound OC[C@H]1CCCN1 HVVNJUAVDAZWCB-RXMQYKEDSA-N 0.000 description 1
108010092160 Dactinomycin Proteins 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
238000006646 Dess-Martin oxidation reaction Methods 0.000 description 1
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
AADVCYNFEREWOS-OBRABYBLSA-N Discodermolide Chemical compound C=C\C=C/[C@H](C)[C@H](OC(N)=O)[C@@H](C)[C@H](O)[C@@H](C)C\C(C)=C/[C@H](C)[C@@H](O)[C@@H](C)\C=C/[C@@H](O)C[C@@H]1OC(=O)[C@H](C)[C@@H](O)[C@H]1C AADVCYNFEREWOS-OBRABYBLSA-N 0.000 description 1
OFDNQWIFNXBECV-UHFFFAOYSA-N Dolastatin 10 Natural products CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)CC)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-UHFFFAOYSA-N 0.000 description 1
206010014824 Endotoxic shock Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102100023688 Eotaxin Human genes 0.000 description 1
101710139422 Eotaxin Proteins 0.000 description 1
HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 1
101710115997 Gamma-tubulin complex component 2 Proteins 0.000 description 1
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
108010008488 Glycylglycine Proteins 0.000 description 1
BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
108010069236 Goserelin Proteins 0.000 description 1
208000003807 Graves Disease Diseases 0.000 description 1
101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 description 1
101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 description 1
101000713081 Homo sapiens C-C motif chemokine 23 Proteins 0.000 description 1
101000916059 Homo sapiens C-X-C chemokine receptor type 2 Proteins 0.000 description 1
101000616438 Homo sapiens Microtubule-associated protein 4 Proteins 0.000 description 1
101000582950 Homo sapiens Platelet factor 4 Proteins 0.000 description 1
102000006992 Interferon-alpha Human genes 0.000 description 1
108010047761 Interferon-alpha Proteins 0.000 description 1
102000003996 Interferon-beta Human genes 0.000 description 1
108090000467 Interferon-beta Proteins 0.000 description 1
108010018976 Interleukin-8A Receptors Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
108010000817 Leuprolide Proteins 0.000 description 1
HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
229910010082 LiAlH Inorganic materials 0.000 description 1
GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
229940126083 M3 antagonist Drugs 0.000 description 1
229930126263 Maytansine Natural products 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
239000012359 Methanesulfonyl chloride Substances 0.000 description 1
UTLKCGPAJUYGOM-UHFFFAOYSA-N Methyl 5-nitro-2-furoate Chemical compound COC(=O)C1=CC=C([N+]([O-])=O)O1 UTLKCGPAJUYGOM-UHFFFAOYSA-N 0.000 description 1
FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 1
229940119336 Microtubule stabilizer Drugs 0.000 description 1
102100021794 Microtubule-associated protein 4 Human genes 0.000 description 1
UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 description 1
208000003926 Myelitis Diseases 0.000 description 1
BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 1
KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
208000025174 PANDAS Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
208000021155 Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection Diseases 0.000 description 1
240000004718 Panda Species 0.000 description 1
235000016496 Panda oleosa Nutrition 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
101150003085 Pdcl gene Proteins 0.000 description 1
206010049752 Peau d'orange Diseases 0.000 description 1
229940117896 Phospholipase D inhibitor Drugs 0.000 description 1
102000009097 Phosphorylases Human genes 0.000 description 1
108010073135 Phosphorylases Proteins 0.000 description 1
102100030304 Platelet factor 4 Human genes 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
206010036595 Premature delivery Diseases 0.000 description 1
AXORVIZLPOGIRG-QMMMGPOBSA-N R-BETA-METHYLPHENYLETHYLAMINE Chemical compound NC[C@H](C)C1=CC=CC=C1 AXORVIZLPOGIRG-QMMMGPOBSA-N 0.000 description 1
208000003782 Raynaud disease Diseases 0.000 description 1
241000447727 Scabies Species 0.000 description 1
229920002536 Scavenger resin Polymers 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
229910004298 SiO 2 Inorganic materials 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
210000000662 T-lymphocyte subset Anatomy 0.000 description 1
102000004243 Tubulin Human genes 0.000 description 1
108090000704 Tubulin Proteins 0.000 description 1
229940122803 Vinca alkaloid Drugs 0.000 description 1
108010046516 Wheat Germ Agglutinins Proteins 0.000 description 1
YPFLFUJKZDAXRA-UHFFFAOYSA-N [3-(carbamoylamino)-2-(2,4-dichlorobenzoyl)-1-benzofuran-6-yl] methanesulfonate Chemical compound O1C2=CC(OS(=O)(=O)C)=CC=C2C(NC(N)=O)=C1C(=O)C1=CC=C(Cl)C=C1Cl YPFLFUJKZDAXRA-UHFFFAOYSA-N 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
229940022663 acetate Drugs 0.000 description 1
WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
239000012346 acetyl chloride Substances 0.000 description 1
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
239000002487 adenosine deaminase inhibitor Substances 0.000 description 1
150000003973 alkyl amines Chemical class 0.000 description 1
229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
150000008052 alkyl sulfonates Chemical class 0.000 description 1
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
230000004075 alteration Effects 0.000 description 1
229960000473 altretamine Drugs 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
229960003437 aminoglutethimide Drugs 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
229960001220 amsacrine Drugs 0.000 description 1
XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000002927 anti-mitotic effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
229940045695 antineooplastic colchicine derivative Drugs 0.000 description 1
229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
229940127218 antiplatelet drug Drugs 0.000 description 1
239000003435 antirheumatic agent Substances 0.000 description 1
239000006286 aqueous extract Substances 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
150000007514 bases Chemical class 0.000 description 1
210000003651 basophil Anatomy 0.000 description 1
229940092705 beclomethasone Drugs 0.000 description 1
NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
230000008901 benefit Effects 0.000 description 1
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
125000005513 benzoazaindolyl group Chemical group 0.000 description 1
125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
239000012148 binding buffer Substances 0.000 description 1
230000008512 biological response Effects 0.000 description 1
YDTYYWHGEGWWTO-UHFFFAOYSA-N bis(2,3,4-trifluorophenyl)methanone Chemical compound FC1=C(F)C(F)=CC=C1C(=O)C1=CC=C(F)C(F)=C1F YDTYYWHGEGWWTO-UHFFFAOYSA-N 0.000 description 1
229960001561 bleomycin Drugs 0.000 description 1
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
230000036765 blood level Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
208000029028 brain injury Diseases 0.000 description 1
LKXYJYDRLBPHRS-UHFFFAOYSA-N bromocyclopropane Chemical compound BrC1CC1 LKXYJYDRLBPHRS-UHFFFAOYSA-N 0.000 description 1
229960004436 budesonide Drugs 0.000 description 1
229960002092 busulfan Drugs 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
229910000024 caesium carbonate Inorganic materials 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
229960004562 carboplatin Drugs 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
229960005243 carmustine Drugs 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
238000000423 cell based assay Methods 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
230000036232 cellulite Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000002559 chemokine receptor antagonist Substances 0.000 description 1
239000005482 chemotactic factor Substances 0.000 description 1
229960004630 chlorambucil Drugs 0.000 description 1
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
208000037893 chronic inflammatory disorder Diseases 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
229960001338 colchicine Drugs 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
238000003271 compound fluorescence assay Methods 0.000 description 1
238000002591 computed tomography Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
229960000265 cromoglicic acid Drugs 0.000 description 1
125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
VSSAZBXXNIABDN-UHFFFAOYSA-N cyclohexylmethanol Chemical compound OCC1CCCCC1 VSSAZBXXNIABDN-UHFFFAOYSA-N 0.000 description 1
125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
HWDVTQAXQJQROO-UHFFFAOYSA-N cyclopropylazanide Chemical compound [NH-]C1CC1 HWDVTQAXQJQROO-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
150000001945 cysteines Chemical class 0.000 description 1
229960000684 cytarabine Drugs 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
229960003901 dacarbazine Drugs 0.000 description 1
229960000640 dactinomycin Drugs 0.000 description 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
229960000975 daunorubicin Drugs 0.000 description 1
125000005070 decynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000017858 demethylation Effects 0.000 description 1
238000010520 demethylation reaction Methods 0.000 description 1
229960001271 desloratadine Drugs 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
229960000452 diethylstilbestrol Drugs 0.000 description 1
229940043279 diisopropylamine Drugs 0.000 description 1
230000010339 dilation Effects 0.000 description 1
FAMGJMYDHOESPR-UHFFFAOYSA-M dilithium;carbanide;bromide Chemical compound [Li+].[Li+].[CH3-].[Br-] FAMGJMYDHOESPR-UHFFFAOYSA-M 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
SXZIXHOMFPUIRK-UHFFFAOYSA-N diphenylmethanimine Chemical compound C=1C=CC=CC=1C(=N)C1=CC=CC=C1 SXZIXHOMFPUIRK-UHFFFAOYSA-N 0.000 description 1
239000002988 disease modifying antirheumatic drug Substances 0.000 description 1
VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
230000009429 distress Effects 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
NOTIQUSPUUHHEH-UXOVVSIBSA-N dromostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 description 1
229950004683 drostanolone propionate Drugs 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
239000012039 electrophile Substances 0.000 description 1
230000026721 endothelial cell chemotaxis Effects 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
210000003979 eosinophil Anatomy 0.000 description 1
229960001904 epirubicin Drugs 0.000 description 1
229930013356 epothilone Natural products 0.000 description 1
HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 1
150000003883 epothilone derivatives Chemical class 0.000 description 1
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
229960005420 etoposide Drugs 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000005284 excitation Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000003527 fibrinolytic agent Substances 0.000 description 1
230000003176 fibrotic effect Effects 0.000 description 1
ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
229960000961 floxuridine Drugs 0.000 description 1
229960000390 fludarabine Drugs 0.000 description 1
229960005304 fludarabine phosphate Drugs 0.000 description 1
125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
229960001751 fluoxymesterone Drugs 0.000 description 1
MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
229960002074 flutamide Drugs 0.000 description 1
229960002714 fluticasone Drugs 0.000 description 1
MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
239000004052 folic acid antagonist Substances 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
229960002848 formoterol Drugs 0.000 description 1
BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
229960002598 fumaric acid Drugs 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
STJIISDMSMJQQK-UHFFFAOYSA-N furan-3-ylmethanol Chemical compound OCC=1C=COC=1 STJIISDMSMJQQK-UHFFFAOYSA-N 0.000 description 1
150000002240 furans Chemical class 0.000 description 1
HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 1
229940043257 glycylglycine Drugs 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
239000010931 gold Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
239000005337 ground glass Substances 0.000 description 1
229940029575 guanosine Drugs 0.000 description 1
125000001188 haloalkyl group Chemical group 0.000 description 1
230000003862 health status Effects 0.000 description 1
UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
102000055357 human CXCR2 Human genes 0.000 description 1
150000002430 hydrocarbons Chemical group 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
RCCPEORTSYDPMB-UHFFFAOYSA-N hydroxy benzenecarboximidothioate Chemical compound OSC(=N)C1=CC=CC=C1 RCCPEORTSYDPMB-UHFFFAOYSA-N 0.000 description 1
150000002440 hydroxy compounds Chemical class 0.000 description 1
230000033444 hydroxylation Effects 0.000 description 1
238000005805 hydroxylation reaction Methods 0.000 description 1
229960002899 hydroxyprogesterone Drugs 0.000 description 1
CUILPNURFADTPE-UHFFFAOYSA-N hypobromous acid Chemical compound BrO CUILPNURFADTPE-UHFFFAOYSA-N 0.000 description 1
229960001101 ifosfamide Drugs 0.000 description 1
HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000005462 in vivo assay Methods 0.000 description 1
238000012750 in vivo screening Methods 0.000 description 1
229960004078 indacaterol Drugs 0.000 description 1
QZZUEBNBZAPZLX-QFIPXVFZSA-N indacaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 QZZUEBNBZAPZLX-QFIPXVFZSA-N 0.000 description 1
125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229910021432 inorganic complex Inorganic materials 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
102000010681 interleukin-8 receptors Human genes 0.000 description 1
108010038415 interleukin-8 receptors Proteins 0.000 description 1
PDJAZCSYYQODQF-UHFFFAOYSA-N iodine monofluoride Chemical compound IF PDJAZCSYYQODQF-UHFFFAOYSA-N 0.000 description 1
HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
229960001361 ipratropium bromide Drugs 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
239000012948 isocyanate Substances 0.000 description 1
150000002513 isocyanates Chemical class 0.000 description 1
YDNLNVZZTACNJX-UHFFFAOYSA-N isocyanatomethylbenzene Chemical compound O=C=NCC1=CC=CC=C1 YDNLNVZZTACNJX-UHFFFAOYSA-N 0.000 description 1
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
238000002372 labelling Methods 0.000 description 1
150000002596 lactones Chemical class 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000001821 langerhans cell Anatomy 0.000 description 1
229960001614 levamisole Drugs 0.000 description 1
KCTBOHUTRYYLJA-UHFFFAOYSA-N lithium;2h-furan-2-ide Chemical compound [Li+].C=1C=[C-]OC=1 KCTBOHUTRYYLJA-UHFFFAOYSA-N 0.000 description 1
239000012160 loading buffer Substances 0.000 description 1
238000011068 loading method Methods 0.000 description 1
229960002247 lomustine Drugs 0.000 description 1
JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
229960003088 loratadine Drugs 0.000 description 1
239000006210 lotion Substances 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000002595 magnetic resonance imaging Methods 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
229940098895 maleic acid Drugs 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
229940099690 malic acid Drugs 0.000 description 1
AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 description 1
238000005259 measurement Methods 0.000 description 1
PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
229960004296 megestrol acetate Drugs 0.000 description 1
RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
229960001924 melphalan Drugs 0.000 description 1
SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
229960001428 mercaptopurine Drugs 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
MLSKXPOBNQFGHW-UHFFFAOYSA-N methoxy(dioxido)borane Chemical compound COB([O-])[O-] MLSKXPOBNQFGHW-UHFFFAOYSA-N 0.000 description 1
VXGABWCSZZWXPC-UHFFFAOYSA-N methyl 2-(methylamino)acetate Chemical compound CNCC(=O)OC VXGABWCSZZWXPC-UHFFFAOYSA-N 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
KQSSATDQUYCRGS-UHFFFAOYSA-N methyl glycinate Chemical compound COC(=O)CN KQSSATDQUYCRGS-UHFFFAOYSA-N 0.000 description 1
229960004584 methylprednisolone Drugs 0.000 description 1
229960001566 methyltestosterone Drugs 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000011707 mineral Substances 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
239000006151 minimal media Substances 0.000 description 1
CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
230000000394 mitotic effect Effects 0.000 description 1
210000000479 mitotic spindle apparatus Anatomy 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000003607 modifier Substances 0.000 description 1
229960001664 mometasone Drugs 0.000 description 1
QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
125000002950 monocyclic group Chemical group 0.000 description 1
125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
229960005127 montelukast Drugs 0.000 description 1
125000002757 morpholinyl group Chemical group 0.000 description 1
230000004660 morphological change Effects 0.000 description 1
239000012452 mother liquor Substances 0.000 description 1
239000003681 muscarinic M3 receptor antagonist Substances 0.000 description 1
UVEWQKMPXAHFST-UHFFFAOYSA-N n,1-diphenylmethanimine Chemical compound C=1C=CC=CC=1C=NC1=CC=CC=C1 UVEWQKMPXAHFST-UHFFFAOYSA-N 0.000 description 1
XBECFEJUQZXMFE-UHFFFAOYSA-N n-(4-aminobutyl)acetamide;hydrochloride Chemical compound Cl.CC(=O)NCCCCN XBECFEJUQZXMFE-UHFFFAOYSA-N 0.000 description 1
XTSSXTWGEJTWBM-FQEVSTJZSA-N n-[(7s)-1,2,3,10-tetramethoxy-9-oxo-6,7-dihydro-5h-benzo[a]heptalen-7-yl]benzamide Chemical compound N([C@H]1CCC=2C=C(C(=C(OC)C=2C2=CC=C(OC)C(=O)C=C21)OC)OC)C(=O)C1=CC=CC=C1 XTSSXTWGEJTWBM-FQEVSTJZSA-N 0.000 description 1
CMEGANPVAXDBPL-INIZCTEOSA-N n-[(7s)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-6,7-dihydro-5h-benzo[a]heptalen-7-yl]acetamide Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(SC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC CMEGANPVAXDBPL-INIZCTEOSA-N 0.000 description 1
BHCJHYIMNHXLOM-WVDRJWPYSA-N n-[(e,2r)-1-(3,4-dichlorophenyl)-5-oxo-5-[[(3r)-2-oxoazepan-3-yl]amino]pent-3-en-2-yl]-n-methyl-3,5-bis(trifluoromethyl)benzamide Chemical compound C([C@@H](N(C)C(=O)C=1C=C(C=C(C=1)C(F)(F)F)C(F)(F)F)\C=C\C(=O)N[C@H]1C(NCCCC1)=O)C1=CC=C(Cl)C(Cl)=C1 BHCJHYIMNHXLOM-WVDRJWPYSA-N 0.000 description 1
IFYDWYVPVAMGRO-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]tetradecanamide Chemical compound CCCCCCCCCCCCCC(=O)NCCCN(C)C IFYDWYVPVAMGRO-UHFFFAOYSA-N 0.000 description 1
HVAAHUDGWQAAOJ-UHFFFAOYSA-N n-benzylethanamine Chemical compound CCNCC1=CC=CC=C1 HVAAHUDGWQAAOJ-UHFFFAOYSA-N 0.000 description 1
125000004370 n-butenyl group Chemical group [H]\C([H])=C(/[H])C([H])([H])C([H])([H])* 0.000 description 1
125000006606 n-butoxy group Chemical group 0.000 description 1
OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
RIWRFSMVIUAEBX-UHFFFAOYSA-N n-methyl-1-phenylmethanamine Chemical compound CNCC1=CC=CC=C1 RIWRFSMVIUAEBX-UHFFFAOYSA-N 0.000 description 1
MCSAQVGDZLPTBS-UHFFFAOYSA-N n-methyl-1-pyridin-3-ylmethanamine Chemical compound CNCC1=CC=CN=C1 MCSAQVGDZLPTBS-UHFFFAOYSA-N 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
125000004957 naphthylene group Chemical group 0.000 description 1
150000002828 nitro derivatives Chemical class 0.000 description 1
125000004971 nitroalkyl group Chemical group 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
229950006344 nocodazole Drugs 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
125000003518 norbornenyl group Chemical group C12(C=CC(CC1)C2)* 0.000 description 1
125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
238000011580 nude mouse model Methods 0.000 description 1
AQFWNELGMODZGC-UHFFFAOYSA-N o-ethylhydroxylamine Chemical compound CCON AQFWNELGMODZGC-UHFFFAOYSA-N 0.000 description 1
125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
239000003605 opacifier Substances 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000012660 pharmacological inhibitor Substances 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
JSSXHAMIXJGYCS-UHFFFAOYSA-N piperazin-4-ium-2-carboxylate Chemical compound OC(=O)C1CNCCN1 JSSXHAMIXJGYCS-UHFFFAOYSA-N 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
125000005936 piperidyl group Chemical group 0.000 description 1
229910003446 platinum oxide Inorganic materials 0.000 description 1
229960003171 plicamycin Drugs 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
125000003367 polycyclic group Chemical group 0.000 description 1
230000037048 polymerization activity Effects 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
229920000137 polyphosphoric acid Polymers 0.000 description 1
238000010837 poor prognosis Methods 0.000 description 1
235000020004 porter Nutrition 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000004323 potassium nitrate Substances 0.000 description 1
235000010333 potassium nitrate Nutrition 0.000 description 1
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
229960005205 prednisolone Drugs 0.000 description 1
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
229960000624 procarbazine Drugs 0.000 description 1
CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
150000003212 purines Chemical class 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
125000000719 pyrrolidinyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
238000001525 receptor binding assay Methods 0.000 description 1
230000010076 replication Effects 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
210000001525 retina Anatomy 0.000 description 1
OWPCHSCAPHNHAV-QIPOKPRISA-N rhizoxin Chemical compound C/C([C@@H]([C@@H](C)[C@H]1OC(=O)[C@@H]2O[C@H]2C[C@@H]2C[C@@H](OC(=O)C2)[C@H](C)/C=C/[C@H]2O[C@]2(C)[C@@H](O)C1)OC)=C\C=C\C(\C)=C\C1=COC(C)=N1 OWPCHSCAPHNHAV-QIPOKPRISA-N 0.000 description 1
MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 1
229960002586 roflumilast Drugs 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
229960004017 salmeterol Drugs 0.000 description 1
229930195734 saturated hydrocarbon Natural products 0.000 description 1
208000005687 scabies Diseases 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
208000013223 septicemia Diseases 0.000 description 1
150000003378 silver Chemical class 0.000 description 1
YPNVIBVEFVRZPJ-UHFFFAOYSA-L silver sulfate Chemical compound [Ag+].[Ag+].[O-]S([O-])(=O)=O YPNVIBVEFVRZPJ-UHFFFAOYSA-L 0.000 description 1
229910000367 silver sulfate Inorganic materials 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
235000009518 sodium iodide Nutrition 0.000 description 1
235000010288 sodium nitrite Nutrition 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
239000011343 solid material Substances 0.000 description 1
230000020347 spindle assembly Effects 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
229960001052 streptozocin Drugs 0.000 description 1
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229950011332 talnetant Drugs 0.000 description 1
229960001603 tamoxifen Drugs 0.000 description 1
150000004579 taxol derivatives Chemical class 0.000 description 1
NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
229960001278 teniposide Drugs 0.000 description 1
229960003604 testosterone Drugs 0.000 description 1
125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
OSBSFAARYOCBHB-UHFFFAOYSA-N tetrapropylammonium Chemical compound CCC[N+](CCC)(CCC)CCC OSBSFAARYOCBHB-UHFFFAOYSA-N 0.000 description 1
150000003536 tetrazoles Chemical group 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
125000001984 thiazolidinyl group Chemical group 0.000 description 1
125000004588 thienopyridyl group Chemical group S1C(=CC2=C1C=CC=N2)* 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
125000004568 thiomorpholinyl group Chemical group 0.000 description 1
CUPOOAWTRIURFT-UHFFFAOYSA-N thiophene-2-carbonitrile Chemical compound N#CC1=CC=CS1 CUPOOAWTRIURFT-UHFFFAOYSA-N 0.000 description 1
229960000103 thrombolytic agent Drugs 0.000 description 1
229960003087 tioguanine Drugs 0.000 description 1
229960000257 tiotropium bromide Drugs 0.000 description 1
XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
229960005026 toremifene Drugs 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 1
229950001353 tretamine Drugs 0.000 description 1
229960005294 triamcinolone Drugs 0.000 description 1
GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
150000003918 triazines Chemical class 0.000 description 1
150000003852 triazoles Chemical group 0.000 description 1
DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 1
ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
239000001226 triphosphate Substances 0.000 description 1
235000011178 triphosphate Nutrition 0.000 description 1
UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
238000001665 trituration Methods 0.000 description 1
230000004565 tumor cell growth Effects 0.000 description 1
229960001055 uracil mustard Drugs 0.000 description 1
210000003556 vascular endothelial cell Anatomy 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
KDQAABAKXDWYSZ-PNYVAJAMSA-N vinblastine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-PNYVAJAMSA-N 0.000 description 1
229960004982 vinblastine sulfate Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
KDQAABAKXDWYSZ-JKDPCDLQSA-N vincaleukoblastine sulfate Chemical compound OS(O)(=O)=O.C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 KDQAABAKXDWYSZ-JKDPCDLQSA-N 0.000 description 1
229960002110 vincristine sulfate Drugs 0.000 description 1
HHJUWIANJFBDHT-KOTLKJBCSA-N vindesine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(N)=O)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 HHJUWIANJFBDHT-KOTLKJBCSA-N 0.000 description 1
229960004355 vindesine Drugs 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
229940033942 zoladex Drugs 0.000 description 1

JP2004543449A 2002-10-09 2003-10-07 Ｃｘｃ−ケモカインレセプターリガンドおよびｃｃ−ケモカインレセプターリガンドとしてのチアジアゾールジオキシドおよびチアジアゾールオキシド Expired - Fee Related JP4664074B2 (ja)